155 related articles for article (PubMed ID: 28646232)
1. Inhibition of ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous Sclerosis.
Pal R; Bondar VV; Adamski CJ; Rodney GG; Sardiello M
Sci Rep; 2017 Jun; 7(1):4174. PubMed ID: 28646232
[TBL] [Abstract][Full Text] [Related]
2. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
3. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
5. Methionine controls insulin/mammalian target of rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability.
Gen S; Matsumoto Y; Suzuki T; Inoue J; Yamamoto Y
Biochem Biophys Res Commun; 2021 Feb; 541():84-89. PubMed ID: 33482580
[TBL] [Abstract][Full Text] [Related]
6. Decreased rates of cerebral protein synthesis measured in vivo in a mouse model of Tuberous Sclerosis Complex: unexpected consequences of reduced tuberin.
Saré RM; Huang T; Burlin T; Loutaev I; Smith CB
J Neurochem; 2018 Jun; 145(5):417-425. PubMed ID: 29364507
[TBL] [Abstract][Full Text] [Related]
7. Tuberin-heterozygous cell line TSC2ang1 as a model for tuberous sclerosis-associated skin lesions.
Wlodarski PK; Maksym R; Oldak M; Jozwiak S; Wojcik A; Jozwiak J
Int J Mol Med; 2008 Feb; 21(2):245-50. PubMed ID: 18204792
[TBL] [Abstract][Full Text] [Related]
8. Brain tumor formation in tuberous sclerosis depends on Erk activation.
Jozwiak J; Grajkowska W; Kotulska K; Jozwiak S; Zalewski W; Zajaczkowska A; Roszkowski M; Slupianek A; Wlodarski P
Neuromolecular Med; 2007; 9(2):117-27. PubMed ID: 17627032
[TBL] [Abstract][Full Text] [Related]
9. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
[TBL] [Abstract][Full Text] [Related]
10. Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury.
Mariappan MM; Prasad S; D'Silva K; Cedillo E; Sataranatarajan K; Barnes JL; Choudhury GG; Kasinath BS
J Biol Chem; 2014 Dec; 289(51):35363-75. PubMed ID: 25339176
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity.
Zhan J; Chitta RK; Harwood FC; Grosveld GC
Mol Cell Biochem; 2019 Jun; 456(1-2):123-134. PubMed ID: 30684133
[TBL] [Abstract][Full Text] [Related]
12. Single serine on TSC2 exerts biased control over mTORC1 activation mediated by ERK1/2 but not Akt.
Dunkerly-Eyring BL; Pan S; Pinilla-Vera M; McKoy D; Mishra S; Grajeda Martinez MI; Oeing CU; Ranek MJ; Kass DA
Life Sci Alliance; 2022 Jun; 5(6):. PubMed ID: 35288456
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia.
Di Nardo A; Lenoël I; Winden KD; Rühmkorf A; Modi ME; Barrett L; Ercan-Herbst E; Venugopal P; Behne R; Lopes CAM; Kleiman RJ; Bettencourt-Dias M; Sahin M
Cell Rep; 2020 Jun; 31(12):107780. PubMed ID: 32579942
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
Krishnamoorthy J; Tenkerian C; Gupta J; Ghaddar N; Wang S; Darini C; Staschke KA; Ghosh A; Gandin V; Topisirovic I; Kristof AS; Hatzoglou M; Simos G; Koromilas AE
Cell Death Dis; 2018 Feb; 9(3):254. PubMed ID: 29449538
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).
Niere F; Namjoshi S; Song E; Dilly GA; Schoenhard G; Zemelman BV; Mechref Y; Raab-Graham KF
Mol Cell Proteomics; 2016 Feb; 15(2):426-44. PubMed ID: 26419955
[TBL] [Abstract][Full Text] [Related]
17. mTORC1 Activity in Psoriatic Lesions Is Mediated by Aberrant Regulation through the Tuberous Sclerosis Complex.
Ferreri A; Lang V; Kaufmann R; Buerger C
Cells; 2022 Sep; 11(18):. PubMed ID: 36139422
[TBL] [Abstract][Full Text] [Related]
18. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
19. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
20. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
